Advanced Cell Technology Comments on Technology Platform
Nov 17, 2008 11:05:00 AM
Copyright Business Wire 2008
Email Story Discuss on ZenoBank
View Additional Profiles
WORCESTER, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (OTC:ACTC) commented today on its technology platform. The Company noted that it believes it has the only technology that can produce stem cell lines of all types without the destruction of the embryo, which should increase the likelihood of receiving federal funding for clinical development. In addition, one of the Company's licensees, International Stem Cell Corporation (ISCO.ob), is using Advanced Cell's parthenogenesis technology, which has the capability of developing some types of stem cells using genetic engineering.
"We believe it is a significant advantage to be able to develop all types of stem cell lines without destroying embryos," said William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology, Inc. "This should enhance the Company's ability to receive funding for development activities at a time when the administration in Washington is changing and opportunities for funding stem cell companies are increasing."
Advanced Cell Technology also licenses some of its non core technology to a subsidiary of Biotime Inc. (OTCBB: BITM) and START, a partnership between Exeter Life Sciences and Geron Corp (NASDAQ: GERN).
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. It currently has approximately 250 million tradable shares in circulation with its laboratory located in Worcester, Massachusetts.
For more information, visit www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2008. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Source: Advanced Cell Technology, Inc.
----------------------------------------------
CEOcast
Inc. for Advanced Cell Technology
Daniel Schustack
212-732-4300
News 
Market Data 
Discover 
